About Spectral AI, Inc. (formerly Spectral MD, Inc.)

Spectral AI, Inc. (formerly Spectral MD, Inc.) is a Dallas-based healthcare AI company specializing in predictive medical diagnostics for wound care. Their flagship product, the DeepView® System, utilizes proprietary AI algorithms combined with multispectral imaging to provide an objective and immediate assessment of a wound’s healing potential. This technology aims to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics that are invisible to the naked eye at the initial presentation of a wound. The DeepView System delivers a binary prediction on whether a wound will heal by a specified time point, assisting physicians in making more accurate, timely, and informed treatment decisions.

The company’s primary focus is on burn indications, an area where early and accurate assessment significantly impacts treatment choices and patient outcomes.S.S. commercial sales, and also obtained initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. Spectral AI has also secured substantial non-dilutive government funding, including a significant contract with the Biomedical Advanced Research and Development Authority (BARDA), to support the development and commercialization of its DeepView System.

Focus Areas

medical diagnostics predictive analytics wound care burn assessment diabetic foot ulcers AI multispectral imaging

Business Intelligence

TechnologyDeepView System combines multispectral imaging with proprietary AI algorithms for wound healing prediction. It is non-invasive, non-radiation, and non-laser, not requiring injectable dye.

What Physicians Need to Know

Specialization
Spectral AI specializes in predictive medical diagnostics, particularly in wound care for burns and diabetic foot ulcers (DFUs). They focus on providing 'Day One' healing predictions to guide treatment decisions.
Key Differentiators
Their DeepViewu00ae System combines AI and multispectral imaging to assess wound healing potential, offering objective and immediate assessments that are not visible to the human eye. The system has shown superior accuracy compared to unaided clinical judgment in burn wound assessment. It also accounts for melanin, providing objective assessments regardless of skin tone.
Technology Stack
The core technology is the DeepViewu00ae Wound Imaging System, a portable multimodal imaging platform. It utilizes proprietary multispectral optics and sensors to capture images across various wavelengths, from visible blue to deep infrared, to analyze tissue physiology and viability biomarkers like hemoglobin oxygenation and tissue hydration. These multispectral data points are integrated with patient clinical data into AI algorithms for wound healing prediction.
Burn Assessment
The DeepViewu00ae System provides a 'Day One' wound healing assessment for burns, with 92% accuracy in predicting if a burn wound will heal or not. This helps clinicians determine the need for surgical intervention sooner, moving away from a 'wait-and-see' approach.
Diabetic Foot Ulcers
For DFUs, the DeepViewu00ae technology provides 86% accuracy in predicting if a DFU will close 50% of its area by week 4. This aims to reduce the reliance on subjective assessments and enable earlier advanced wound care therapies, potentially preventing amputations.
AI and Predictive Analytics
Spectral AI's predictive AI algorithms distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye. The company owns the largest burn biopsy tissue bank and extensive burn and DFU image databases, which are used to train and improve their AI models.
Regulatory Status & Funding
The DeepViewu00ae System for Burn Indication received De Novo Classification from the U.S. FDA in May 2026, allowing for U.S. commercialization. It also received initial UKCA authorization in the United Kingdom in February 2024. The company has secured over $130 million in U.S. Government contracts, including from BARDA, to support its technology development.
Physician Tip

For physicians, Spectral AI's DeepViewu00ae System offers objective, immediate, and highly accurate wound healing predictions for burns and diabetic foot ulcers, directly at the point of care. This can significantly improve triage, treatment planning, and patient outcomes by enabling earlier interventions and reducing the 'wait-and-see' period. The non-contact and fast image acquisition (0.2 seconds for acquisition, 20-25 seconds for AI processing) makes it practical for real-world clinical settings. The system's ability to 'see the unknown' below the skin surface provides crucial information that traditional visual assessments miss, leading to more informed decisions and potentially reducing healthcare costs.

Spectral AI is working on EHR interoperability and clinical documentation workflows. Their clinical application pipeline includes future opportunities for AI-3D wound measurement, AI-Venous Leg Ulcer (VLU) indication, AI-Critical Limb Ischemia (CLI) indication, AI-Digital Health, AI-Guided Therapy, and AI-Cosmetics, leveraging their universal imaging platform.

Products by Spectral AI, Inc. (formerly Spectral MD, Inc.)

No products listed for this company yet. Know of one? Suggest it →

Videos

News, demos, and interviews about Spectral AI, Inc. (formerly Spectral MD, Inc.).

Loading videos...

Videos load interactively. If none appear, search YouTube for Spectral AI, Inc. (formerly Spectral MD, Inc.) →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Spectral AI's core technology is the DeepViewu00ae System, which combines AI and multispectral imaging to provide immediate, objective predictions of wound healing potential. This non-invasive device captures physiological information not visible to the human eye, enabling faster and more accurate treatment decisions for conditions like burns and diabetic foot ulcers.
The DeepViewu00ae System has demonstrated superior accuracy in identifying non-healing burn tissue compared to burn physicians' clinical judgment. In studies, DeepView achieved 86.6% sensitivity in identifying non-healing tissue at an image-wise level, while clinical judgment scored 40.8%.
Currently, Spectral AI's DeepViewu00ae System is cleared for burn assessment and is being developed for diabetic foot ulcers (DFUs). The company plans to expand its AI platform to include other indications such as AI-3D wound measurement, venous leg ulcers (VLUs), and critical limb ischemia (CLI).
Spectral AI's DeepViewu00ae System received FDA De Novo Classification in May 2026, authorizing its commercial distribution in the United States for burn care. It also received initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024.
Spectral AI offers support for implementing standardized assessment protocols, clinician training, and patient education programs. They also provide technical program support for optics and sensor integration, electronic hardware design, and clinical pathway implementation.
While specific details on DeepView's data security were not extensively detailed, Spectral AI emphasizes its focus on AI governance in healthcare, aiming for 90-95% visibility into AI usage to enforce policy at runtime and detect PHI exposure and policy violations within minutes.
Spectral AI, Inc. (MDAI) is a publicly traded company on NASDAQ. As of September 23, 2026, its shares were valued at $1.67 with a market cap of $53.59 million. The company has received over $130 million in U.S. Government contracts to support its technology development.

Related Companies

Stanford University, through its online learning platform Stanford Online (online.stanford.edu), provides a wide array of educational opportunities, including those focused on Artificial Intelligence (AI) in healthcare. Stanford Online aims to extend the university’s academic excellence and breakthrough research to a global audience, offering programs taught by Stanford faculty and industry experts. These offerings range from […]

RTW.ai provides scaled CPA services, offering productized accounting, tax preparation, and quarterly insights specifically for owner-led businesses in healthcare, professional services, and the trades. The company aims to eliminate the common frustrations associated with traditional accounting services, such as slow response times and lack of proactive tax planning. They commit to closing books by the […]

Trainio is an AI roleplay training platform specifically designed for healthcare teams. It allows medical staff, including front desk personnel, call center agents, caregivers, nurses, and pharmacists, to practice challenging patient and family conversations with realistic AI avatars. These scenarios cover a wide range of situations, such as de-escalation of angry patients, communication with individuals […]

Infinitus is a healthcare AI company that develops voice AI agents and copilots to automate administrative workflows for physicians and healthcare providers. The company aims to reduce the complexity and cost of healthcare by handling time-consuming and repetitive phone-based tasks, such as benefit verifications, prior authorizations, patient outreach, and member engagement. By automating these processes, […]

Confido Health is an AI-powered healthcare operations platform designed to alleviate administrative burdens for physicians and healthcare providers. The company develops AI agents that automate routine tasks and workflows across various aspects of healthcare operations, including front, mid, and back office functions. This allows medical staff to dedicate more time to direct patient care, improving […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.